Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
NCT ID: NCT02210819
Last Updated: 2019-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1987 participants
OBSERVATIONAL
2014-06-27
2017-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main goal is to analyze long-term safety in the use of rivaroxaban in the treatment of acute VTE in routine clinical practice.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
NCT01619007
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
NCT02558465
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
NCT01516814
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
NCT02064439
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
NCT01516840
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rivaroxaban
Patients who will be treated for an acute venous thromboembolism (VTE) with rivaroxaban.
Rivaroxaban (Xarelto, BAY59-7939)
Cohort participants are classified as "rivaroxaban" patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine
Standard of care
Patients who will be treated for an acute venous thromboembolism (VTE) with current standard of care.
Recommended VTE pharmacological treatments according to international guidelines
Cohort participants are classified as "Standard of care" patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rivaroxaban (Xarelto, BAY59-7939)
Cohort participants are classified as "rivaroxaban" patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine
Recommended VTE pharmacological treatments according to international guidelines
Cohort participants are classified as "Standard of care" patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute DVT and/or PE, objectively confirmed
* Indication for anticoagulation therapy for at least 12 weeks
* Willing to participate in this study and available for follow-up
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Multiple Locations, , Algeria
Multiple Locations, , Egypt
Multiple Locations, , Indonesia
Multiple Locations, , Jordan
Multiple Locations, , Kazakhstan
Multiple Locations, , Kenya
Multiple Locations, , Kuwait
Multiple Locations, , Lebanon
Multiple Locations, , Malaysia
Multiple Locations, , Mexico
Multiple Locations, , Morocco
Multiple Locations, , Philippines
Multiple Locations, , Qatar
Multiple Locations, , Russia
Multiple Locations, , Saudi Arabia
Multiple Locations, , Singapore
Multiple Locations, , South Korea
Multiple Locations, , Taiwan
Multiple Locations, , Turkey (Türkiye)
Multiple Locations, , Ukraine
Multiple Locations, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XA1402
Identifier Type: OTHER
Identifier Source: secondary_id
17237
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.